# A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China

> **NCT03572231** · — · COMPLETED · sponsor: **Astellas Pharma Singapore Pte. Ltd.** · enrollment: 805 (actual)

## Conditions studied

- Overactive Bladder (OAB)

## Interventions

- **DRUG:** mirabegron
- **DEVICE:** solifenacin
- **DRUG:** darifenacin
- **DRUG:** imidafenacin
- **DRUG:** tolterodine
- **DRUG:** oxybutynin
- **DRUG:** trospium
- **DRUG:** fesoterodine
- **DEVICE:** propiverine

## Key facts

- **NCT ID:** NCT03572231
- **Lead sponsor:** Astellas Pharma Singapore Pte. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-19
- **Primary completion:** 2020-03-30
- **Final completion:** 2020-03-30
- **Target enrollment:** 805 (ACTUAL)
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03572231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03572231, "A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT03572231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*